The metabolite BH4 controls T cell proliferation in autoimmunity and cancer
- Nature. 2018 Nov;563(7732):564-568. doi: 10.1038/s41586-018-0701-2.
- 1. IMBA, Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria.
- 2. Department of Neurobiology, Harvard Medical School, Boston, MA, USA.
- 3. FM Kirby Neurobiology Center, Boston Children's Hospital, Boston, MA, USA.
- 4. Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, AUVA Research Center, Vienna, Austria.
- 5. Département de Pharmacologie et Physiologie, Université de Montréal, Montréal, Québec, Canada.
- 6. Institute for Molecular Medicine, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.
- 7. Department of Internal Medicine II (Infectious Diseases, Immunology, Rheumatology and Pneumology), Medical University of Innsbruck, Innsbruck, Austria.
- 8. Institute of Chemical Sciences and Engineering, Institute of Bioengineering, National Centre of Competence in Research (NCCR) in Chemical Biology, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
- 9. Division of Cardiovascular Medicine, British Heart Foundation Centre for Research Excellence, John Radcliffe Hospital, University of Oxford, Oxford, UK.
- 10. Wellcome Trust Centre for Human Genetics, Roosevelt Drive, University of Oxford, Oxford, UK.
- 11. Division of Gastroenterology and Liver Center, Department of Medicine, Beth Israel Deaconess Medical Center (BIDMC) and Harvard Medical School (HMS), Harvard University, Boston, MA, USA.
- 12. LABOX, Departamento de Bioquímica, Universidade Federal de Santa Catarina, Florianópolis, Brazil.
- 13. Research Institute of Molecular Pathology, Vienna Biocenter, Campus-Vienna-Biocenter 1, Vienna, Austria.
- 14. Karolinska Institute, Department of Medicine Solna, Center for Molecular Medicine, Karolinska University Hospital Solna, Stockholm, Sweden.
- 15. Department of Neuronal Control of Metabolism, Max Planck Institute for Metabolism Research, Cologne, Germany.
- 16. Department of Neurosciences, Centre de Recherche de CHU de Québec-Université Laval, Québec, Québec, Canada.
- 17. Department of Molecular Medicine, Faculty of Medicine, Université Laval, Québec, Quebec, Canada.
- 18. Neurosurgery Department, Johns Hopkins School of Medicine, Baltimore, MD, USA.
- 19. Apeiron Biologics AG, Vienna, Austria.
- 20. Quartet Medicine, 400 Technology Square, Cambridge, MA, USA.
- 21. Department of Anesthesia, Harvard Medical School, Boston, MA, USA.
- 22. Boston Children's Hospital, Boston, MA, USA.
- 23. Department of Chemical Biology, Max-Planck Institute for Medical Research, Heidelberg, Germany.
- 24. Department of Neurobiology, Harvard Medical School, Boston, MA, USA. [email protected].
- 25. FM Kirby Neurobiology Center, Boston Children's Hospital, Boston, MA, USA. [email protected].
- 26. IMBA, Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria. [email protected].
Genetic regulators and environmental stimuli modulate T cell activation in autoimmunity and Cancer. The enzyme co-factor tetrahydrobiopterin (BH4) is involved in the production of monoamine neurotransmitters, the generation of nitric oxide, and pain1,2. Here we uncover a link between these processes, identifying a fundamental role for BH4 in T Cell Biology. We find that genetic inactivation of GTP cyclohydrolase 1 (GCH1, the rate-limiting enzyme in the synthesis of BH4) and inhibition of sepiapterin reductase (the terminal enzyme in the synthetic pathway for BH4) severely impair the proliferation of mature mouse and human T cells. BH4 production in activated T cells is linked to alterations in iron metabolism and mitochondrial bioenergetics. In vivo blockade of BH4 synthesis abrogates T-cell-mediated autoimmunity and allergic inflammation, and enhancing BH4 levels through GCH1 overexpression augments responses by CD4- and CD8-expressing T cells, increasing their antitumour activity in vivo. Administration of BH4 to mice markedly reduces tumour growth and expands the population of intratumoral effector T cells. Kynurenine-a tryptophan metabolite that blocks antitumour immunity-inhibits T cell proliferation in a manner that can be rescued by BH4. Finally, we report the development of a potent SPR antagonist for possible clinical use. Our data uncover GCH1, SPR and their downstream metabolite BH4 as critical regulators of T Cell Biology that can be readily manipulated to either block autoimmunity or enhance Anticancer immunity.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: Carbonyl ReductaseResearch Areas: Inflammation/Immunology
-
target: Reactive Oxygen Species (ROS)Research Areas: Inflammation/Immunology